CNN26m
Opus Genetics, Inc.
Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders.
Southwest Airline’s activist investor concerns won’t disappear after the deal with Elliott
In June, Elliott disclosed a $1.9 billion stake in Southwest and proceeded to spend the summer skewering the Dallas-based ...
FTSE 100's Vodafone set for pivotal update as Three merger gains traction
Shares in the London-listed firm have barely moved this year, up just over three per cent since January, despite a number of attempts to revive interest in the stock ...
Trump's tariffs will make it hard for automakers — including Tesla — to set up shop in Mexico
Donald Trump's idea of imposing 200%-plus tariffs on vehicles imported from Mexico could throw the US auto industry into ...
Noel Gallagher was no more biased than Gary Neville – TNT should welcome him back
Noel Gallagher’s appearance as a co-commentator may have shocked some but why should the role be the sole preserve of former ...
U.S. News & World Report8h
SoftBank Expected to Book $1.87 Billion Profit on IPOs
The net profit forecast for July-September is based on the average of four analyst estimates compiled by the London Stock ...
Satellite Images and Documents Indicate China Working on Nuclear Propulsion for New Aircraft Carrier
For the first time, a group of U.S. researchers has concluded that China has built a land-based prototype nuclear reactor to ...
Business Insider14h
Analysts’ Opinions Are Mixed on These Technology Stocks: Block (SQ), Akamai (AKAM) and Sprout Social (SPT)
Block (SQ) Robert W. Baird analyst David Koning maintained a Buy rating on Block on November 8 and set a price target of $100.00. The company’s shares closed last Friday at $74.56. According to ...